Everolimus: A Challenging Drug in the Treatment of Multifocal Inoperable Cardiac Rhabdomyoma

DEMIR H. A., Ekici F., ERDEM A. Y., EMIR S., TUNC B.

PEDIATRICS, vol.130, no.1, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 130 Issue: 1
  • Publication Date: 2012
  • Doi Number: 10.1542/peds.2011-3476
  • Journal Name: PEDIATRICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: cardiac, heart, rhabdomyoma, newborn, child, everolimus, TUBEROUS SCLEROSIS, TUMORS, CHILDREN, INFANCY, MTOR
  • Akdeniz University Affiliated: No

Abstract

Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment. Pediatrics 2012; 130: e243-e247